IN2015DN02630A - - Google Patents

Info

Publication number
IN2015DN02630A
IN2015DN02630A IN2630DEN2015A IN2015DN02630A IN 2015DN02630 A IN2015DN02630 A IN 2015DN02630A IN 2630DEN2015 A IN2630DEN2015 A IN 2630DEN2015A IN 2015DN02630 A IN2015DN02630 A IN 2015DN02630A
Authority
IN
India
Prior art keywords
present disclosure
methods
disclosure relates
mammalian cells
increased levels
Prior art date
Application number
Other languages
English (en)
Inventor
Amit; Varma
James; Cuenca
Ying; Zhu
Original Assignee
Abbvie Biotherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Biotherapeutics Inc filed Critical Abbvie Biotherapeutics Inc
Publication of IN2015DN02630A publication Critical patent/IN2015DN02630A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/005—Glycopeptides, glycoproteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2806—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2842—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IN2630DEN2015 2012-10-01 2013-09-27 IN2015DN02630A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261708554P 2012-10-01 2012-10-01
PCT/US2013/062410 WO2014055370A1 (en) 2012-10-01 2013-09-27 Compostions and methods for producing glycoproteins

Publications (1)

Publication Number Publication Date
IN2015DN02630A true IN2015DN02630A (zh) 2015-09-18

Family

ID=49354940

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2630DEN2015 IN2015DN02630A (zh) 2012-10-01 2013-09-27

Country Status (27)

Country Link
US (2) US20150259425A1 (zh)
EP (1) EP2904092B1 (zh)
JP (1) JP6351598B2 (zh)
KR (1) KR102182885B1 (zh)
CN (1) CN104797707A (zh)
AU (1) AU2013327681B2 (zh)
BR (1) BR112015007319B1 (zh)
CA (1) CA2886753C (zh)
CY (1) CY1119602T1 (zh)
DK (1) DK2904092T3 (zh)
EA (1) EA201590550A1 (zh)
ES (1) ES2646594T3 (zh)
HK (1) HK1207394A1 (zh)
HR (1) HRP20171753T1 (zh)
HU (1) HUE034896T2 (zh)
IL (1) IL237916A0 (zh)
IN (1) IN2015DN02630A (zh)
LT (1) LT2904092T (zh)
ME (1) ME02882B (zh)
MX (1) MX366106B (zh)
NO (1) NO2760138T3 (zh)
PL (1) PL2904092T3 (zh)
PT (1) PT2904092T (zh)
RS (1) RS56641B1 (zh)
SG (2) SG10201702448WA (zh)
SI (1) SI2904092T1 (zh)
WO (1) WO2014055370A1 (zh)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106170298B (zh) 2013-10-16 2024-01-09 前瞻疗法公司 用于提高抗体稳定性的缓冲液制剂
CA2966005C (en) 2014-10-31 2021-04-27 Abbvie Biotherapeutics Inc. Anti-cs1 antibodies and antibody drug conjugates
EP3247718B1 (en) 2015-01-21 2021-09-01 Outlook Therapeutics, Inc. Modulation of charge variants in a monoclonal antibody composition
JP2019500878A (ja) * 2016-01-06 2019-01-17 オンコバイオロジクス，インコーポレイティド モノクローナル抗体組成物中の高分子量種、酸性荷電種、及び断片の低減
CN109153716A (zh) * 2016-01-06 2019-01-04 安口生物公司 调节单克隆抗体组合物中的非岩藻糖基化物类
JP7084308B2 (ja) 2016-02-03 2022-06-14 アウトルック セラピューティクス，インコーポレイティド 抗体安定性を増大させるための緩衝液製剤
EP3420072A4 (en) * 2016-02-22 2019-08-28 Agency for Science, Technology and Research CELL CULTURE MEDIUM
JP7406990B2 (ja) * 2016-11-11 2023-12-28 ホワイトヘッド・インスティテュート・フォー・バイオメディカル・リサーチ ヒト血漿様培地
CN111944050B (zh) * 2020-08-19 2022-05-13 苏州普乐康医药科技有限公司 一种抗b7-h3抗体及其应用
CN113337562B (zh) * 2021-05-24 2022-06-03 宁波人健药业集团股份有限公司 使用CHO细胞高效发酵生产rhCG的方法
CN113480632B (zh) * 2021-07-30 2023-02-03 宁波人健药业集团股份有限公司 一种在CHO细胞中表达的重组蛋白rhCG纯化工艺

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444887A (en) 1979-12-10 1984-04-24 Sloan-Kettering Institute Process for making human antibody producing B-lymphocytes
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4716111A (en) 1982-08-11 1987-12-29 Trustees Of Boston University Process for producing human antibodies
US4510245A (en) 1982-11-18 1985-04-09 Chiron Corporation Adenovirus promoter system
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4968615A (en) 1985-12-18 1990-11-06 Ciba-Geigy Corporation Deoxyribonucleic acid segment from a virus
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5413923A (en) 1989-07-25 1995-05-09 Cell Genesys, Inc. Homologous recombination for universal donor cells and chimeric mammalian hosts
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
DE69133566T2 (de) 1990-01-12 2007-12-06 Amgen Fremont Inc. Bildung von xenogenen Antikörpern
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
KR100272077B1 (ko) 1990-08-29 2000-11-15 젠팜인터내셔날,인코포레이티드 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
IE922437A1 (en) 1991-07-25 1993-01-27 Idec Pharma Corp Recombinant antibodies for human therapy
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
ES2341666T3 (es) 1991-12-02 2010-06-24 Medimmune Limited Produccion de autoanticuerpos de repertorios de segmentos de anticue rpos expresados en la superficie de fagos.
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
KR20050085971A (ko) 1995-04-27 2005-08-29 아브게닉스, 인크. 면역화된 제노마우스 유래의 인간 항체
AU2466895A (en) 1995-04-28 1996-11-18 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5705364A (en) 1995-06-06 1998-01-06 Genentech, Inc. Mammalian cell culture process
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
EP2314625B1 (en) 1996-12-03 2014-05-07 Amgen Fremont Inc. Transgenic mammals having human Ig loci including plural VH and Vkappa regions and antibodies produced therefrom
US7227002B1 (en) 1997-04-14 2007-06-05 Micromet Ag Human antibodies that bind human 17-A1/EpCAM tumor antigen
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
US6900056B2 (en) * 2001-02-15 2005-05-31 Centocor, Inc. Chemically defined medium for cultured mammalian cells
US7709610B2 (en) 2003-05-08 2010-05-04 Facet Biotech Corporation Therapeutic use of anti-CS1 antibodies
ES2376556T3 (es) 2004-03-24 2012-03-14 Abbott Biotherapeutics Corp. Utilización de la anticuerpos anti-alfa5beta1 para inhibir la proliferación de las células cancerosas.
AU2005335714B2 (en) 2004-11-10 2012-07-26 Macrogenics, Inc. Engineering Fc antibody regions to confer effector function
KR20100053607A (ko) 2007-08-03 2010-05-20 패시트 바이오테크 코포레이션 항-ｔｗｅａｋ 수용체 항체의 치료 용도

Also Published As

Publication number Publication date
MX2015004027A (es) 2015-10-29
EP2904092A1 (en) 2015-08-12
KR20150063441A (ko) 2015-06-09
HK1207394A1 (zh) 2016-01-29
NO2760138T3 (zh) 2018-08-04
SG11201502339YA (en) 2015-04-29
AU2013327681A1 (en) 2015-04-09
SI2904092T1 (en) 2018-01-31
WO2014055370A1 (en) 2014-04-10
ME02882B (me) 2018-04-20
HUE034896T2 (hu) 2018-03-28
US20150259425A1 (en) 2015-09-17
IL237916A0 (en) 2015-05-31
CN104797707A (zh) 2015-07-22
BR112015007319A2 (pt) 2017-08-08
PL2904092T3 (pl) 2018-02-28
CY1119602T1 (el) 2018-04-04
PT2904092T (pt) 2017-12-06
HRP20171753T1 (hr) 2017-12-29
CA2886753A1 (en) 2014-04-10
JP6351598B2 (ja) 2018-07-04
DK2904092T3 (en) 2017-12-11
MX366106B (es) 2019-06-27
LT2904092T (lt) 2017-12-11
SG10201702448WA (en) 2017-04-27
BR112015007319B1 (pt) 2022-02-15
ES2646594T3 (es) 2017-12-14
AU2013327681B2 (en) 2019-01-24
JP2015532096A (ja) 2015-11-09
CA2886753C (en) 2021-01-26
EA201590550A1 (ru) 2015-09-30
US20170152540A1 (en) 2017-06-01
KR102182885B1 (ko) 2020-11-25
RS56641B1 (sr) 2018-03-30
EP2904092B1 (en) 2017-09-20

Similar Documents

Publication Publication Date Title
IN2015DN02630A (zh)
IL297998B2 (en) Mammalian cell culture
MY169935A (en) "a method for reducing heterogeneity of antibodies and a process of producing the antibodies thereof"
MY161726A (en) Biological methods for preparing adipic acid
MX2019003427A (es) Composiciones para cultivo celular y metodos para la produccion de polipeptidos.
MX2014003212A (es) Microorganismos y metodos para producir alquenos.
WO2015004403A3 (fr) Procede de culture cellulaire decouple
IN2014DN09244A (zh)
MX2014015768A (es) Microorganismo recombinante para la produccion fermentativa de metionina.
MX2013007650A (es) Metodo de cultivo de celulas animales.
MX2015011781A (es) Medio de cultivo celular y metodos de produccion de anticuerpos.
EP2582792A4 (en) HEART OF CARDIOMYOCYTES WITH DIALYSATED SERUM
MX344896B (es) Método de operación de la fermentación de un substrato gaseoso que contiene monóxido de carbono.
MX2020001357A (es) Produccion microbiana de aminas grasas.
WO2014049382A3 (en) Ethylenediamine fermentative production by a recombinant microorganism
IN2014DN09097A (zh)
IN2014MN01621A (zh)
MX2014012407A (es) Metodo para incrementar la secrecion de proteinas recombinantes.
MY189384A (en) Biological methods for preparing adipic acid
UA71656U (ru) Способ диагностики эндогенной интоксикации
UA67620U (ru) Способ выделения мезенхимальных мультипотентных стромальных клеток
GB201119202D0 (en) Device and method
GB201105503D0 (en) Microcarrier for the culture if stem cells, method of culturing stem cells and method of using said microcarrier